Monte Rosa Therapeutics (GLUE) Other financing activities (2021 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Other financing activities of $4.5 million for Q1 2026, up 32200.0% year-over-year from N/an in Q1 2025, and down 15.65% quarter-over-quarter from $5.4 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) Other financing activities (2021 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Other financing activities history runs 6 years deep, the most recent figure standing at $4.5 million for Q1 2026.
- In Q1 2026, Other financing activities rose 32200.0% year-over-year to $4.5 million; the TTM figure through Mar 2026 stood at $10.2 million (up 1134.14% YoY), while the FY2025 annual figure was $5.7 million, up 439.4% from the prior year.
- Other financing activities for Q1 2026 stood at $4.5 million, down from $5.4 million in the prior quarter.
- The five-year high for Other financing activities was $49.8 million in Q2 2024, with the low at -$49.3 million in Q3 2024.
- The 5-year median for Other financing activities is $246000.0 (2024), against an average of $810294.1.
- The sharpest annual moves came in 2024 and 2026: Other financing activities tumbled 2979.04% in 2024, then surged 32200.0% in 2026.
- Monte Rosa Therapeutics' Other financing activities stood at $439000.0 in 2022, then tumbled by 96.81% to $14000.0 in 2023, then soared by 2607.14% to $379000.0 in 2024, then surged by 1314.51% to $5.4 million in 2025, then decreased by 15.65% to $4.5 million in 2026.
- Business Quant data shows GLUE's Other financing activities at $4.5 million in Q1 2026, $5.4 million in Q4 2025, and $362000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.60 Mn |
| Jun 30, 2026 | 2.60 Mn |
| Mar 31, 2026 | 4.52 Mn |
| Mar 31, 2026 | 4.52 Mn |
| Dec 31, 2025 | 5.36 Mn |
| Dec 31, 2025 | 5.36 Mn |
| Sep 30, 2025 | 362,000.00 |
| Sep 30, 2025 | 362,000.00 |
| Jun 30, 2025 | -14,000.00 |
| Jun 30, 2025 | -14,000.00 |
| Mar 31, 2025 | 14,000.00 |
| Mar 31, 2025 | 14,000.00 |
| Dec 31, 2024 | 379,000.00 |
| Dec 31, 2024 | 379,000.00 |
| Sep 30, 2024 | -49.32 Mn |
| Sep 30, 2024 | -49.32 Mn |
| Jun 30, 2024 | 49.75 Mn |
| Jun 30, 2024 | 49.75 Mn |
| Mar 31, 2024 | 246,000.00 |
| Mar 31, 2024 | 246,000.00 |